Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Est. Listeners
Insufficient chart data. Estimates will improve as the show charts.
- Per-Episode Audience
Est. listeners per new episode within ~30 days
N/A🎙 ~2x weekly·1,000 episodes·Last published 1w ago - Monthly Reach
Unique listeners across all episodes (30 days)
N/A - Active Followers
Loyal subscribers who consistently listen
N/A
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 15 epsHosts
Recent guests
Recent episodes
Weekly Wrap 12 June
Jun 12, 2026
9m 36s
Weekly Wrap 5 June
Jun 5, 2026
6m 35s
Weekly Wrap 22 May
May 22, 2026
12m 39s
Weekly Wrap 15 May
May 15, 2026
15m 36s
From the helm: Solstice Minerals (ASX:SLS), Managing Director and CEO Nick Castleden
May 15, 2026
10m 51s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 6/12/26 | Weekly Wrap 12 June✨ | market analysisUS equities+5 | — | SpaceXRBA | Middle East | Middle EastTrump+5 | — | 9m 36s | |
| 6/5/26 | Weekly Wrap 5 June✨ | ASX performancemacroeconomic factors+5 | Will Riggall | Bell Financial GroupBell Potter+1 | — | ASXmacroeconomics+7 | — | 6m 35s | |
| 5/22/26 | Weekly Wrap 22 May✨ | market analysisbond markets+5 | — | Bell PotterRBA | — | marketsbond markets+5 | — | 12m 39s | |
| 5/15/26 | Weekly Wrap 15 May✨ | federal budgetAI demand+4 | Will RiggallRob Crookston | Bell Financial GroupBell Potter | Australia | federal budgetAI+7 | — | 15m 36s | |
| 5/15/26 | From the helm: Solstice Minerals (ASX:SLS), Managing Director and CEO Nick Castleden✨ | explorationcopper-gold project+3 | Nick Castleden | Solstice MineralsBell Direct | NanadieASX | Solstice MineralsNanadie+5 | — | 10m 51s | |
| 5/8/26 | Weekly Wrap 8 May✨ | market volatilityoil prices+3 | Will Riggall | Bell Financial GroupBell Potter | Australia | market movesoil prices+3 | — | 9m 09s | |
| 5/1/26 | Weekly Wrap 1 May✨ | US economyearnings report+4 | — | MetaAlphabet+2 | USAustralia | Wall StreetMeta+6 | — | 12m 18s | |
| 4/24/26 | Weekly Wrap 24 April✨ | market volatilitygeopolitical tensions+4 | — | crude oilCochlear+1 | Wall Streetglobal+1 | market volatilitygeopolitical tensions+5 | — | 11m 03s | |
| 4/17/26 | Weekly Wrap 17 April✨ | market analysisinvestment strategies+3 | Rob Crookston | Bell PotterS&P 500 | United States | market rallyS&P 500+3 | — | 13m 45s | |
| 4/1/26 | From the helm: Oneview Healthcare (ASX:ONE), CEO, James Fitter✨ | patient monitoring technologyAI impact+3 | James Fitter | Oneview HealthcareASX | — | Oneview HealthcareJames Fitter+5 | — | 4m 25s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 4/1/26 | From the helm: Centaurus Metals (ASX:CTM), CEO & MD, Darren Gordon✨ | Centaurus Metalsnickel market+3 | Darren Gordon | nickelCentaurus Metals+1 | — | Centaurus MetalsDarren Gordon+3 | — | 6m 33s | |
| 4/1/26 | From the helm: Titomic Ltd, CFO, Geoff Hollis✨ | metal manufacturingproprietary technology+3 | Geoff Hollis | Titomic LtdBell Direct+1 | — | TitomicCFO+5 | — | 8m 34s | |
| 4/1/26 | From the helm: Artrya Limited (ASX:AYA): John Konstantopoulos, CEO & Co-Founder✨ | AI in healthcarecardiac diagnostics+3 | John Konstantopoulos | Artrya LimitedASX:AYA | — | Artrya LimitedAI+3 | — | 7m 58s | |
| 4/1/26 | From the helm: Bell Financial Group (ASX:BFG): Arnie Selvarajah, Group Co-CEO✨ | wealth managementstockbroking+3 | Arnie Selvarajah | Bell Financial GroupBell Direct+1 | — | Bell Financial Groupwealth management+3 | — | 9m 46s | |
| 3/31/26 | Navigating geopolitical turbulence:The strategic case for defence technology✨ | defence technologygeopolitical turbulence+3 | Billy Leung | Bell Financial GroupGlobal X | USIran | defence stocksmilitary investment+3 | — | 17m 14s | |
| 3/27/26 | Weekly Wrap 27 March | In today’s Weekly Wrap episode, Will Riggall and Sophia Mavridis chat about the key insights heard at the ASX SMIDcaps conference this week, proudly sponsored by Bell Financial Group. Our CIO Will Riggall and Lead Strategist Rob Crookston provided a keynote presentation and a range of CEOs spoke about the opportunities in some of the ASX’s up and coming stocks. Hear about Will’s macroeconomic outlook in the face of the ongoing Middle East conflict as well as high quality opportunities withi... | 12m 45s | ||||||
| 3/20/26 | From the helm: Summerset Group Holdings (ASX:SNZ), CFO, Margaret Warrington. | In this episode of From the Helm, Grady sits down with Summerset Group Holdings (ASX:SNZ) CFO Margaret Warrington to unpack their end-to-end business model for aged care sites, from land acquisition all the way through to building and operating the centres. | 10m 57s | ||||||
| 3/20/26 | From the helm: Amplia Therapeutics (ASX:ATX), CEO & MD, Christopher Burns & Bell Potter Analyst, Thomas Wakim. | In this episode of From the Helm, Grady is joined by Amplia Therapeutics (ASX:ATX) CEO & MD Dr Christopher Burns & Bell Potter Analyst Thomas Wakim to unpack the ongoing clinical trials for their prospective treatment drug for pancreatic cancer, and its substantial market opportunities in the US. | 13m 49s | ||||||
| 3/20/26 | From the helm: Alterity Therapeutics (ASX:ATH), CEO, David Stamler. | In this episode of From the Helm, Grady chats with Alterity Therapeutics (ASX:ATH) CEO David Stamler, to discuss their neurodegenerative disorder treatment specifically targeting Multiple System Atrophy (MSA), a rare and aggressive disease affecting involuntary functions and motor control. | 11m 10s | ||||||
| 3/20/26 | From the helm: Neuren Pharmaceuticals (ASX:NEU), CEO, Jon Pilcher. | In this episode of From the Helm, Grady sits down with Neuren Pharmaceuticals (ASX:NEU) CEO Jon Pilcher, to recap on their major developments over the last 12 months in the US market, their guidance looking ahead for next financial year, and the company’s healthy cash balance. | 15m 25s | ||||||
| 3/20/26 | From the helm: Saluda Medical (ASX:SLD), President & CEO, Barry Regan | In this episode of From the Helm, Grady chats with Saluda Medical (ASX:SM1) President and CEO Barry Regan to discuss their recent developments since their IPO in November, their developmental drug for the treatment of chronic pain, and what is on the horizon looking ahead. | 17m 10s | ||||||
| 3/20/26 | From the helm: Clarity Pharma (ASX:CU6), Chair, Alan Taylor & Senior Bell Potter Analyst John Hester | In this episode of From the Helm, Grady is joined by Clarity Pharmaceuticals (ASX:CU6) Executive Chairperson Alan Taylor & Bell Potter Senior Analyst John Hester, for a deep dive into their next-generation radiopharmaceutical technology for both early-stage cancer diagnosis and treatment. | 16m 12s | ||||||
| 3/20/26 | From the helm: Mesoblast (ASX:MSB), Director, Silviu Itescu | In this episode of From the Helm, Grady sits down with Mesoblast Director Silviu Itescu, to unpack the recent approval and launch of their Ryoncil drug for children, their outlook for the next 12 months in capturing the adult market, and their extensive pipeline of further products. | 8m 48s | ||||||
| 3/20/26 | From the helm: 4DMedical (ASX:4DX), Founder & CEO, Andreas Fouras | In this episode of From the helm, Grady chats with 4D Medical (ASX:4DX) Founder and CEO Andreas Fouras to reflect on the meteoric rise of their lung imaging technology and detail their future plans for further global expansion. | 12m 53s | ||||||
| 3/20/26 | From the helm: EBR Systems (ASX:EBR), President & CEO, John McCutcheon | In this episode of From the Helm, Grady sits down with EBR Systems (ASX:EBR) President and CEO John McCutcheon, to discuss their innovative, one-of-a-kind implant treatment for heart failure patients, the pathway to widespread adoption, and scaling plans for future growth. | 7m 24s | ||||||
Showing 25 of 935
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.